...
首页> 外文期刊>OncoTargets and therapy >HGF and NRG1 protein expression are not poor prognostic markers in?surgically resected lung adenocarcinoma
【24h】

HGF and NRG1 protein expression are not poor prognostic markers in?surgically resected lung adenocarcinoma

机译:HGF和NRG1蛋白表达在手术切除的肺腺癌中不是不良的预后标志物

获取原文
           

摘要

Purpose: Although over-expression of hepatocyte growth factor (HGF) and neuregulin-1 (NRG1) are important mechanisms involved in acquired drug-resistance in many cancers, few reports have evaluated their clinicopathologic features and prognostic significance. The aim of our study was to investigate protein expressions of HGF and NRG1 in lung adenocarcinomas and their association with clinicopathologic parameters, oncogenic mutations, and the prognosis. Methods: HGF and NRG1 protein tumor/stroma expressions were evaluated by immunohistochemistry (IHC) in 115 surgically resected lung adenocarcinomas and were correlated with clinicopathologic and molecular variables including tumor size, tumor node metastasis stage, differentiation, oncogenic mutations (EGFR, KRAS, HER2, BRAF) and ALK fusions, relapse-free survival, and overall survival. Results: Positive?IHC HGF tumor and stroma staining were found in 49 (42.61%) and 12 (10.43%) cases, respectively, while positive?IHC?NRG1?tumor and stroma staining were found in 56 (48.70%) and eleven (9.57%) cases, respectively. Dual positive IHC?HGF?and NRG1 tumor staining was 12.17%. EML4-ALK fusion more significantly existed in HGF-tumor positive samples (P=0.03), positive NRG1 protein stroma expression was significantly associated with male sex (P=0.04), while HGF and NRG1 dual tumor-positive mainly existed in the tumor size >3?cm group (P=0.0231). No significant clinically prognostic difference was found between patients with HGF/NRG1-positive expression and those with HGF/NRG1-negative expression. Conclusion: This study represents the first comprehensive analysis of HGF and NRG1 tumor and stroma expressions in patients with surgically resected lung adenocarcinomas. Our molecular data, in conjunction with clinical and pathological features, as well as their effects on survival indicated to us that patients with HGF- and NRG1-negative expression tended to have better survival, but these results probably did not warrant these markers to be indicators of poor prognosis.
机译:目的:尽管肝细胞生长因子(HGF)和神经调节蛋白1(NRG1)的过表达是许多癌症中获得性耐药的重要机制,但很少有报道评估其临床病理特征和预后意义。我们研究的目的是研究HGF和NRG1在肺腺癌中的蛋白表达及其与临床病理参数,致癌突变和预后的关系。方法:通过免疫组织化学(IHC)评价115例手术切除的肺腺癌中HGF和NRG1蛋白的肿瘤/基质表达,并将其与临床病理和分子变量相关,包括肿瘤大小,肿瘤结节转移阶段,分化,致癌突变(EGFR,KRAS,HER2) ,BRAF)和ALK融合,无复发生存期和总体生存期。结果:分别在49例(42.61%)和12例(10.43%)病例中发现IHC HGF肿瘤和基质染色阳性,而在56例(48.70%)和11例中IHC HNGN1肿瘤和基质染色阳性。分别为9.57%)。 IHC?HGF?和NRG1双重阳性染色为12.17%。 HML肿瘤阳性样本中EML4-ALK融合更为明显(P = 0.03),NRG1蛋白基质阳性表达与男性明显相关(P = 0.04),而HGF和NRG1双重肿瘤阳性主要存在于肿瘤大小> 3?cm组(P = 0.0231)。 HGF / NRG1阳性表达的患者和HGF / NRG1阴性表达的患者之间没有显着的临床预后差异。结论:这项研究代表了首次手术切除的肺腺癌患者中HGF,NRG1肿瘤和基质表达的全面分析。我们的分子数据,结合临床和病理学特征以及它们对生存的影响,向我们表明,HGF-和NRG1阴性表达的患者倾向于有更好的生存率,但是这些结果可能不能保证这些标志物可以作为指标预后不良。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号